Jin Han1,2,3, Jifang Zhou2, Santosh L Saraf3, Victor R Gordeuk3, Gregory S Calip2,4. 1. Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA. 2. Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA. 3. Comprehensive Sickle Cell Center, Section of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA. 4. Division of Public Health Sciences, Epidemiology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Abstract
PURPOSE: Opioid analgesics are commonly used to treat vaso-occlusive pain episodes in sickle cell disease (SCD), but comprehensive evidence characterizing opioid use in this patient population is limited. Our objective was to characterize opioid use patterns among SCD patients using a large nationwide database. METHODS: A large, US medical claims database was utilized to identify a cohort of 3882 SCD patients, and characteristics of opioid use were analyzed. Clinical variables including age, gender, medication use, health care utilization, and medical history were evaluated for correlations with opioid use. RESULTS: Forty percent of patients took opioid medications during a 12-month span, and the prevalence of any opioid use was highest for 20 to 29-year-old patients (58%). The median daily opioid dose was 1.85 mg (interquartile range: 0.62-10.68 mg) oral morphine equivalents (OME). While most opioid users took between 0 and 5 mg OME daily, 3% of pediatric patients and 23% of adult patients used more than 30-mg OME daily. High-dose opioid use was associated with older age, hydroxyurea therapy, nonsteroidal anti-inflammatory drug (NSAID) use, and frequent inpatient hospitalizations. In multivariable-adjusted analyses, patients with vaso-occlusive complications such as pain crisis (OR = 3.8, 95% CI 2.7-5.3) and avascular necrosis (AVN) (OR = 3.7, 95% CI 2.7-5.1) were associated with high-dose opioid use. CONCLUSIONS: Our study showed that only 40% SCD patients were on opioid analgesics during a 12-month span. However, a non-trivial number of patients used a much higher dose of opioids despite a relatively low average daily opioid dose among SCD patients, particularly with vaso-occlusive complications.
PURPOSE: Opioid analgesics are commonly used to treat vaso-occlusive pain episodes in sickle cell disease (SCD), but comprehensive evidence characterizing opioid use in this patient population is limited. Our objective was to characterize opioid use patterns among SCDpatients using a large nationwide database. METHODS: A large, US medical claims database was utilized to identify a cohort of 3882 SCDpatients, and characteristics of opioid use were analyzed. Clinical variables including age, gender, medication use, health care utilization, and medical history were evaluated for correlations with opioid use. RESULTS: Forty percent of patients took opioid medications during a 12-month span, and the prevalence of any opioid use was highest for 20 to 29-year-old patients (58%). The median daily opioid dose was 1.85 mg (interquartile range: 0.62-10.68 mg) oral morphine equivalents (OME). While most opioid users took between 0 and 5 mg OME daily, 3% of pediatric patients and 23% of adult patients used more than 30-mg OME daily. High-dose opioid use was associated with older age, hydroxyurea therapy, nonsteroidal anti-inflammatory drug (NSAID) use, and frequent inpatient hospitalizations. In multivariable-adjusted analyses, patients with vaso-occlusive complications such as pain crisis (OR = 3.8, 95% CI 2.7-5.3) and avascular necrosis (AVN) (OR = 3.7, 95% CI 2.7-5.1) were associated with high-dose opioid use. CONCLUSIONS: Our study showed that only 40% SCDpatients were on opioid analgesics during a 12-month span. However, a non-trivial number of patients used a much higher dose of opioids despite a relatively low average daily opioid dose among SCDpatients, particularly with vaso-occlusive complications.
Authors: Samir K Ballas; Robert L Bauserman; William F McCarthy; Oswaldo L Castro; Wally R Smith; Myron A Waclawiw Journal: Am J Hematol Date: 2010-08 Impact factor: 10.047
Authors: Nicholas T Vozoris; Xuesong Wang; Hadas D Fischer; Chaim M Bell; Denis E O'Donnell; Peter C Austin; Anne L Stephenson; Sudeep S Gill; Paula A Rochon Journal: Eur Respir J Date: 2016-07-13 Impact factor: 16.671
Authors: Mercy Mvundura; Djesika Amendah; Patricia L Kavanagh; Philippa G Sprinz; Scott D Grosse Journal: Pediatr Blood Cancer Date: 2009-10 Impact factor: 3.167
Authors: P F Milner; A P Kraus; J I Sebes; L A Sleeper; K A Dukes; S H Embury; R Bellevue; M Koshy; J W Moohr; J Smith Journal: N Engl J Med Date: 1991-11-21 Impact factor: 91.245
Authors: Patrick H Finan; C Patrick Carroll; Gyasi Moscou-Jackson; Marc O Martel; Claudia M Campbell; Alex Pressman; Joshua M Smyth; Jean-Michel Tremblay; Sophie M Lanzkron; Jennifer A Haythornthwaite Journal: J Pain Date: 2017-09-21 Impact factor: 5.820
Authors: Hyeun Ah Kang; Jamie C Barner; Kristin M Richards; Menaka Bhor; Jincy Paulose; Abdullah Kutlar Journal: J Health Econ Outcomes Res Date: 2020-06-26
Authors: Jifang Zhou; Jin Han; Edith A Nutescu; Victor R Gordeuk; Santosh L Saraf; Gregory S Calip Journal: Br J Haematol Date: 2018-05-16 Impact factor: 6.998
Authors: Joyce T Da Silva; Janelle E Letzen; Jennifer A Haythornthwaite; Patrick H Finan; Claudia M Campbell; David A Seminowicz Journal: Pain Date: 2019-09 Impact factor: 7.926